文献速递胸部腹部乳腺MRCT

接受新辅助化疗的乳腺癌患者化疗相关脂肪性肝炎与心外膜脂肪组织体积增加并存

Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy.
PubMed 文献 · Eur Radiol · 2022-04-08

回顾性分析2018年10月至2020年4月662例乳腺癌患者,NAC组217例、非NAC组445例,用MRI mDIXON-Quant评估化疗相关脂肪性肝炎患病率、胸部CT量化心外膜脂肪组织体积。NAC组化疗相关脂肪性肝炎患病率42.8%高于非NAC组肝脂肪变性33.3%(p<0.001),NAC组EAT体积137.26±53.48 mL高于非NAC组125.14±58.77 mL(p=0.020),肝脂肪含量对EAT体积的间接效应为2.545(p<0.001),贡献率69.1%。

要点

  • 乳腺癌NAC组化疗相关脂肪性肝炎患病率42.8%,高于非NAC组肝脂肪变性33.3%(p<0.001)。
  • NAC组心外膜脂肪组织体积137.26±53.48 mL,高于非NAC组125.14±58.77 mL(p=0.020)。
  • NAC组肝脂肪含量对EAT体积的间接效应为2.545(p<0.001),贡献率69.1%。

核心结论

  • 乳腺癌NAC组心外膜脂肪组织体积显著高于非NAC组,化疗相关脂肪性肝炎患病率在NAC组更高,肝脂肪含量通过中介效应引起EAT体积变化。

研究设计与样本

  • 回顾性研究,纳入2018年10月至2020年4月662例乳腺癌患者(非NAC组445例、NAC组217例),采用MRI mDIXON-Quant定量肝脂肪分数评估化疗相关脂肪性肝炎,胸部CT半自动体积分析软件量化EAT体积,Bootstrap分析检验中介效应。

关键影像表现/征象

  • NAC组心外膜脂肪组织体积137.26±53.48 mL,高于非NAC组125.14±58.77 mL(p=0.020)。
  • EAT体积在662例乳腺癌患者中的561例进行了测量。

诊断标准与关键数值

  • 采用MRI mDIXON-Quant测定的质子密度脂肪分数(PDFF)既定截断值定义肝脂肪变性,据此评估化疗相关脂肪性肝炎患病率;NAC组患病率42.8%,非NAC组肝脂肪变性患病率33.3%(p<0.001)。
  • NAC组肝脂肪含量对EAT体积的间接效应为2.545(p<0.001),贡献率69.1%。

临床应用与阅片要点

  • 乳腺癌NAC患者化疗相关脂肪性肝炎患病率可达42.8%,阅片时需关注肝脏脂肪定量结果。
  • NAC患者心外膜脂肪组织体积较非NAC患者升高,胸部CT量化EAT体积可提供额外信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the prevalence of chemotherapy-associated steatohepatitis, quantitate the epicardial adipose tissue (EAT) volume in breast cancer patients, and explore the mediating effect of liver fat content on EAT volume in breast cancer patients who received neoadjuvant chemotherapy (NAC).

METHODS: From October 2018 to April 2020, patients were retrospectively reviewed and divided into breast cancer non-NAC and NAC groups. The prevalence of chemotherapy-associated steatohepatitis was evaluated through quantitative MRI mDIXON-Quant examinations by using defined proton density fat fraction cutoffs of liver fat. The EAT volume was quantified on chest CT by semi-automatic volume analysis software. Bootstrap analysis was used in the breast cancer NAC group to test the significance of the mediating effect of liver fat content on EAT volume.

RESULTS: A total of 662 breast cancer patients (non-NAC group: 445 patients; NAC group: 217 patients) were included. The prevalence of chemotherapy-associated steatohepatitis in the NAC group was significantly higher than the prevalence of hepatic steatosis in the non-NAC group (42.8% vs. 33.3%, p < 0.001). EAT volume was measured in 561 of 662 breast cancer patients, and was significantly higher in the NAC group than in the non-NAC group (137.26 ± 53.48 mL vs. 125.14 ± 58.77 mL, p = 0.020). In the breast cancer NAC group, the indirect effect of liver fat content on EAT volume was 2.545 (p < 0.001), and the contribution rate to the effect was 69.1%.

CONCLUSIONS: EAT volume was significantly higher in the BC-NAC group than in the BC-non-NAC group.

KEY POINTS: • The prevalence of CASH was as high as 42.8% in BC patients. • NAC significantly increased the EAT volume in BC patients. • The liver fat content caused the change of EAT volume through mediating effect.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang, Tan, Liu, et al. Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy. Eur Radiol. 2022. PMID: 35394181. doi:10.1007/s00330-022-08581-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。